Skip to main content
رجوع
NURPF logo

Neuren Pharmaceuticals Limited

جودة البيانات: 100%
ذروة بيع
NURPF
OTC Healthcare Biotechnology
KWD 8.22
KWD 0.00 (0.00%)
القيمة السوقية: 1.04B
نطاق اليوم
KWD 8.22 KWD 8.22
نطاق 52 أسبوعًا
KWD 6.60 KWD 14.80
حجم التداول
100
متوسط 50 يوم / 200 يوم
KWD 10.28 / KWD 11.44
الإغلاق السابق
KWD 8.22

Quick Summary

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (631 نظير)

المقياس السهم وسيط القطاع
P/E 34.2 0.2
P/B 3.1 3.0
ROE % 8.7 3.6
Net Margin % 47.1 3.8
Rev Growth 5Y % 112.0 9.9
D/E 0.0 0.2

السعر المستهدف للمحللين

لا تتوفر تغطية محللين

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2029 KWD 5.91
KWD 3.68 – KWD 7.55
1.31B 2
FY2028 KWD 1.29
KWD 0.80 – KWD 1.65
299.06M 3
FY2027 KWD 0.56
KWD 0.35 – KWD 0.72
175.14M 2

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-25 KWD 0.00 KWD 0.08 +8091.8%
2025-08-26 KWD 0.08 KWD 0.08 -0.3%
2025-02-27 KWD 0.64 KWD 0.64 -0.9%
2024-08-27 KWD 0.07 KWD 0.04 -44.0%
2024-02-29 KWD 0.67 KWD 0.57 -15.1%
2023-06-30 KWD 0.21 KWD 0.24 +14.5%
2022-12-31 N/A KWD 0.04
2022-06-30 N/A -KWD 0.04

Dividend History

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

النقاط الرئيسية

Revenue grew 112.02% annually over 5 years — strong growth
Earnings declined -78.58% over the past year
Net margin of 47.09% shows strong profitability
Debt/Equity of 0.00 — conservative balance sheet
Generating 125.34M in free cash flow
P/E of 34.22 — premium valuation

النمو

Revenue Growth (5Y)
112.02%
Revenue (1Y)-70.20%
Earnings (1Y)-78.58%
FCF Growth (3Y)-17.66%

الجودة

Return on Equity
8.67%
ROIC4.88%
Net Margin47.09%
Op. Margin34.07%

الأمان

Debt / Equity
0.00
Current Ratio76.60
Interest Coverage0.00

التقييم

P/E Ratio
34.22
Forward P/E65.34
P/B Ratio3.08
EV/EBITDA47.09
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -70.20% Revenue Growth (3Y) -47.22%
Earnings Growth (1Y) -78.58% Earnings Growth (3Y) -55.99%
Revenue Growth (5Y) 112.02% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 64.61M Net Income (TTM) 30.42M
ROE 8.67% ROA 8.88%
Gross Margin 99.96% Operating Margin 34.07%
Net Margin 47.09% Free Cash Flow (TTM) 125.34M
ROIC 4.88% FCF Growth (3Y) -17.66%
Safety
Debt / Equity 0.00 Current Ratio 76.60
Interest Coverage 0.00
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 34.22 Forward P/E 65.34
P/B Ratio 3.08 P/S Ratio 16.11
PEG Ratio -1.05 Forward PEG N/A
EV/EBITDA 47.09 Fwd EV/EBITDA 65.22
Forward P/S 12.80 Fwd Earnings Yield 1.53%
FCF Yield 12.04%
Market Cap 1.04B Enterprise Value 1.04B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 64.61M 216.83M 231.93M 14.55M 3.20M
Net Income 30.42M 142.04M 157.08M 184,000.0 -7.79M
EPS (Diluted) 0.24 1.09 1.20 0.00 -0.07
Gross Profit 64.59M 183.86M 205.17M 14.54M 3.19M
Operating Income 22.02M 146.19M 172.49M -1.60M -17.75M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 342.72M 409.71M 247.97M 43.27M 40.06M
Total Liabilities 4.40M 45.80M 42.76M 1.68M 803,000.0
Shareholders' Equity 338.32M 363.90M 205.21M 41.59M 39.25M
Total Debt 0.0 0.0 0.0 0.0 0.0
Cash & Equivalents 4.23M 3.15M 17.09M 40.18M 36.78M
Current Assets 332.10M 399.33M 247.16M 43.25M 40.04M
Current Liabilities 4.34M 45.76M 42.76M 1.68M 803,000.0